Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.5 SEK | +13.03% |
|
+31.94% | +7.59% |
Jul. 01 | SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon | CI |
May. 31 | SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 314M 3.3B |
---|---|---|---|---|---|
Net income 2022 | -99M -1.04B | Net income 2023 | -216M -2.27B | EV / Sales 2022 | - |
Net cash position 2022 | 106M 1.11B | Net cash position 2023 | 61.76M 648M | EV / Sales 2023 | - |
P/E ratio 2022 |
-22.7
x | P/E ratio 2023 |
-1.33
x | Employees | 5 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.19% |
1 day | +13.03% | ||
1 week | +31.94% | ||
Current month | +32.68% | ||
1 month | +35.81% | ||
3 months | +17.57% | ||
6 months | +13.23% | ||
Current year | +7.59% |
![Extreme 6.96](/images/extremecours_fleche.png)
![Extreme 6.855](/images/extremecours_fleche.png)
![Extreme 4.975](/images/extremecours_fleche.png)
![Extreme 4.975](/images/extremecours_fleche.png)
![Extreme 4.975](/images/extremecours_fleche.png)
![Extreme 4.975](/images/extremecours_fleche.png)
![Extreme 4.75](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Björn Westberg
DFI | Director of Finance/CFO | 62 | 23-05-31 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | Feb. 14 |
Thomas Boesen
COO | Chief Operating Officer | - | 21-01-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Jonassen
CTO | Chief Tech/Sci/R&D Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-07-03 | 9.5 | +13.03% | 424 011 |
24-07-02 | 8.405 | +8.59% | 214,244 |
24-07-01 | 7.74 | +8.10% | 237,305 |
24-06-28 | 7.16 | -0.56% | 64,483 |
24-06-27 | 7.2 | 0.00% | 55,484 |
Delayed Quote Nasdaq Stockholm, July 03, 2024 at 12:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+7.59% | 32.68M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- SYNACT Stock